Vancouver, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global cell therapy market size was USD 4.77 Billion in 2022 and is expected to register a rapid revenue CAGR of 16.3% during the forecast period. This surge is fueled by a surge in cell therapy clinical studies, a growing prevalence of chronic conditions, and technological advancements in regenerative medicine.
Key Market Drivers
The escalating number of clinical studies, especially in oncology, is a prime driver of this growth. With an estimated 1.9 million new cancer diagnoses in the U.S. alone in 2022, cell-based therapies are increasingly considered for their potential to replace or regenerate damaged tissues. Regulatory bodies, like the FDA, are actively supporting advanced therapy development, fostering a conducive environment for market expansion.
Innovation and Initiatives
Cutting-edge approaches such as direct cellular reprogramming are gaining popularity due to their effectiveness and security. Clinical studies for advanced therapeutics are on the rise, with notable developments like Bayer AG's inauguration of a Cell Therapy Launch Facility in Berkeley, California, aimed at advancing treatments for Parkinson's Disease.
Get Free Sample Report and Related Graphs & Charts @ https://www.emergenresearch.com/request-sample/2549
Challenges and Constraints
Despite the promising outlook, ethical concerns in stem cell research, clinical challenges in therapy development, and high costs associated with cell-based research pose challenges. Strict regulatory guidelines also contribute to the complexity of the market.
Market Segmentation
Cell Type Insights:
- Stem cells dominate, holding the largest revenue share in 2022. Mesenchymal Stem Cells (MSCs) play a crucial role, with initiatives like Cedars-Sinai's groundbreaking clinic supported by an USD 8 million grant.
- T cells show promise, particularly in treating chronic diseases. FDA approvals for therapies like Breyanzi indicate a trajectory of moderate revenue growth.
Therapy Type Insights:
- Autologous therapies lead with significant market share due to advantages like easy availability, lower risk, and affordability. FDA approvals, such as ciltacabtagene autoleucel for multiple myeloma, contribute to the segment's growth.
- Allogeneic therapies witness steady growth, addressing the need for stem cell transplantation in treating various blood malignancies. Recent FDA approval of Omisirge underscores the potential in allogeneic treatments.
Click to Purchase this Report at an Exclusively Discounted Rate @ https://www.emergenresearch.com/request-discount/2549
Application Insights:
- Oncology stands out with the fastest revenue growth rate. Increasing cancer prevalence and FDA-approved therapies like Abecma for multiple myeloma contribute to this trajectory.
- Musculoskeletal disorders claim the largest revenue share, driven by extensive research aimed at regenerating or repairing injured musculoskeletal tissues.
Regional Insights:
- North America dominates the market, fueled by a high prevalence of cancer and musculoskeletal disorders. Collaborative efforts between companies like Immatics and Bristol Myers Squibb further drive research initiatives.
- Asia Pacific is poised for the fastest growth, propelled by a large population, increasing health awareness, and government initiatives. Notably, Immuno Adoptive Cell Therapy's CD19-targeted CAR-T cell Therapy product received regulatory approval in India.
- Europe secures a considerable market share, driven by increasing cell therapy transplantation procedures and R&D efforts. Noteworthy is RHEACELL's national approval for its cell therapy product AMESANAR.
Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/2549
Scope of Research
| Report Details | Outcome |
| Market Size in 2022 | USD 4.77 Billion |
| CAGR (2023–2032) | 16.3% |
| Revenue Forecast To 2032 | USD 21.69 Billion |
| Base Year For Estimation | 2022 |
| Historical Data | 2019–2021 |
| Forecast Period | 2023–2032 |
| Quantitative Units | Revenue in USD Billion and CAGR in % from 2023 to 2032 |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | Cell type, therapy type, technology, application, end-use, and region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Country Scope | U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Benelux, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, and Rest of Middle East & Africa |
| Key Companies Profiled | JCR Pharmaceuticals Co., Ltd., NuVasive, Inc., Kolon TissueGene, Inc., Mesoblast Ltd., Medipost Co., Stemedica Cell Technologies, Inc., Novartis AG, Gilead Sciences, Inc., Tegoscience, Atara Biotherapeutics, Inc., Takeda Pharmaceutical Company Limited., Bluebird bio, Inc., Dendreon Pharmaceuticals LLC, Thermo Fisher Scientific Inc., Becton, Dickinson, and Company, Lonza, Sartorius AG, Castle Creek Biosciences, Inc., Anterogen Co., Ltd., and Celgene Corporation |
| Customization Scope | 10 hours of free customization and expert consultation |
Major Companies and Competitive Landscape
The global cell therapy market is fragmented, with many medium and large-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing novel cell therapies. Some major players included in the global cell therapy market report are:
- JCR Pharmaceuticals Co., Ltd.
- NuVasive, Inc.
- Kolon TissueGene, Inc.
- Mesoblast Ltd.
- Medipost Co.
- Stemedica Cell Technologies, Inc.
- Novartis AG
- Gilead Sciences, Inc.
- Tegoscience
- Atara Biotherapeutics, Inc.
- Takeda Pharmaceutical Company Limited
- bluebird bio, Inc.
- Dendreon Pharmaceuticals LLC.
- Thermo Fisher Scientific Inc.
- Becton, Dickinson, and Company
- Lonza
- Sartorius AG
- Castle Creek Biosciences, Inc.
- Anterogen Co., Ltd.
- Celgene Corporation
Strategic Development
- In December 2022, Kite, a Gilead Company, and Arcellx, Inc. announced a global strategic collaboration to co-develop and co-commercialize CART-ddBCMA, Arcellx's flagship late-stage product candidate for the treatment of relapsed or refractory multiple myeloma. CART-ddBCMA is an experimental cell treatment product in Phase 2 clinical development that consists of autologous T cells that have been genetically engineered to target multiple myeloma.
- In January 2022, Cellino Biotech, a cell treatment manufacturing company recently secured USD 80 million in a Series A investment round. By 2025, the company will develop the world's first autonomous human cell foundry. The aim of this project is to make stem cell-based medical therapies more widely available, potentially enhancing the field of regenerative medicine.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/cell-therapy-market
Segments Covered in Report
For the purpose of this report, Emergen research has segmented the global cell therapy market on the basis of cell type, therapy type, technology, application, end-use, and region:
- Cell Type Outlook (Revenue, USD Billion; 2019-2032)
- Stem Cell
- T Cells
- Others
- Therapy Type Outlook (Revenue, USD Billion; 2019-2032)
- Autologous
- Allogeneic
- Technology Outlook (Revenue, USD Billion; 2019-2032)
- Viral Vector Technology
- Genome Editing Technology
- Somatic Cell Technology
- Cell Immortalization Technology
- Cell Plasticity Technology
- Three-dimensional Technology
- Application Outlook (Revenue, USD Billion; 2019-2032)
- Oncology
- Musculoskeletal Disorder
- Autoimmune Disorders
- Dermatology
- Cardiovascular
- Ocular
- Others
- End-use Outlook (Revenue, USD Billion; 2019-2032)
- Hospitals & Clinics
- Biopharmaceutical and Biotechnology Companies
- Contract Research Organizations (CROs)/Contract Manufacturing Organizations (CMOs)
- Regenerative Medicine Centers
- Others
- Regional Outlook (Revenue, USD Billion; 2019–2032)
- North America
-
-
-
- U.S.
- Canada
- Mexico
-
-
-
- Europe
-
-
-
- Germany
- France
- UK
- Italy
- Spain
- Benelux
- Rest of Europe
-
-
-
- Asia Pacific
-
-
-
- China
- India
- Japan
- South Korea
- Rest of APAC
-
-
-
- Latin America
-
-
-
- Brazil
- Rest of LATAM
-
-
-
- Middle East & Africa
-
-
-
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of Middle East & Africa
-
-
Curated Reports You Shouldn't Miss: Dive In Now!
Transcatheter Mitral Valve Implantation Market Analysis, By Product (Mechanical Valves & Bioprosthetic Tissue (Biological) Valves), By Application (Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regurgitation), By End Use (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers), Forecasts to 2027
Blockchain in Healthcare Market By Type (Permissioned/Private Blockchain, Permissionless/Public Blockchain), By Application, By End-Users (Pharmaceutical Companies, Healthcare Providers, Healthcare Payers), Forecasts to 2027
Sports Medicine Market By Product (Body Reconstruction Products, Body Support and Recovery Products), By Application (Knee Injuries, Shoulder Injuries, Foot and Ankle Injuries), By Body Monitoring and Evaluation Devices, By End-Use, and By Region, and By Region, Forecasts to 2027
Artificial Organs Market By Organ Type (Artificial Kidney, Liver, Heart, Lungs, Pancreas), By Usage (Implantable, Extracorporeal), By Material Type (Silicon, Plastic, Steel), Forecasts to 2027
3D Bioprinting Market, By Component, By Application (Research Applications, Clinical Applications), By End-use (Research Organizations and Academic Institutes, Biopharmaceutical Companies), By Region Forecast to 2032
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights
